T Cell Lymphoma Leukemia C4025186
A malignancy involving T-cells that may present as lymphoma or leukemia depending on the case. Treatment typically includes chemotherapy.
Key facts at a glance
- ICD-10
- C91.50, C91.51, C91.52
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Sudden severe headache
Fatigue
(hematologic)Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Lymphadenopathy
(hematologic)Bone pain
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intensive leukemia-style chemotherapy
High-intensity multi-drug chemotherapy protocols similar to acute lymphoblastic leukemia treatment, often including L-asparaginase and CNS prophylaxis.
Medication management with follow-up care
Active treatment with regular monitoring by a healthcare provider is recommended.
Allogeneic stem cell transplant
Bone marrow transplantation from a matched donor to provide graft-versus-leukemia effect and replace diseased hematopoietic cells.
Additional treatment options
Immunotherapy (monoclonal antibodies, CAR-T)
Engineered immune cells or monoclonal antibodies designed to recognize and destroy malignant T-cells, available through clinical trials or specialized centers.
medicationMinimal residual disease monitoring
Highly sensitive molecular testing to detect residual disease at levels below conventional microscopy, guiding treatment decisions.
monitoringNutritional support and hydration management
Enteral or parenteral nutrition support with electrolyte management to maintain strength during intensive chemotherapy and prevent malnutrition.
dietarySources and references
Authoritative medical sources used to create this content.
Anderson JK, Williams RD. NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphoma. J Natl Compr Canc Netw. 2023.
Fujimoto H, Martinez GA, Kimura S. Pathophysiology and treatment of adult T-cell leukemia-lymphoma. Blood Rev. 2021.
Tanaka K, O'Brien LM, Rodriguez VC. Mogamulizumab versus vorinostat in relapsed/refractory adult T-cell leukemia-lymphoma. Lancet Oncol. 2022.
Chen WH, Nakamura Y, Patel R. Systematic review and meta-analysis of first-line therapies for peripheral T-cell lymphoma. Ann Oncol. 2020.
Medication Comparisons
Compare medications used to treat T Cell Lymphoma Leukemia C4025186. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy